Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are...

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”...

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis...

Form 4 - Statement of changes in beneficial ownership of securities

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq:...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malforma

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or...

Form 8-K - Current report

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the...

Form 8-K - Current report

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market

Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic...